Kim Hyun Kuk, Lim Kyung Seob, Kim Sung Soo, Na Joo-Young
Department of Cardiovascular Medicine, Chosun University Medical School, Gwangju, Korea.
Futuristic Animal Resource and Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Korea.
Chonnam Med J. 2021 May;57(2):132-138. doi: 10.4068/cmj.2021.57.2.132. Epub 2021 May 24.
Following acute myocardial infarction (AMI), early use of beta-blockers (BBs) reduced the incidences of ventricular arrhythmia (VA) and death in the pre reperfusion era. However, some studies have reported a worsening of clinical outcomes and therefore, this study used a porcine model of AMI to evaluate the efficacy of bisoprolol on VAs and mortality. Twenty pigs were divided into two groups with one group using oral bisoprolol which was given for 3 hours before the experiment and then maintained for 7 days. A loop recorder was implanted, AMI was induced by balloon occlusion for 60 min, and then, reperfusion. One week later, the echocardiography and loop recorder data were analyzed in the surviving animals. Bisoprolol did not increase the heart rate (62.9±14.5 vs 79.0±20.3; p=0.048), lower the rate of premature ventricular contractions (PVC) (0.8±0.8 vs 11.0±12.8; p=0.021) or tend to lower recurrent VA (0.6±0.5 vs 1.1±1.1; p=0.131) during coronary artery occlusion. After reperfusion, bisoprolol did reduce VA in the early AMI period (0.1±0.3 vs 4.2±4.6; p=0.001) and it was not associated with the extent of myocardial recovery. In this porcine model, early oral bisoprolol might help reduce the incidences of PVC and recurrent VA and determine whether effects are more pronounced during the early AMI period. Our results suggest that bisoprolol might help reduce lethal VA and cardiac death following AMI in this reperfusion era.
在急性心肌梗死(AMI)后,β受体阻滞剂(BBs)的早期使用在再灌注前时代降低了室性心律失常(VA)的发生率和死亡率。然而,一些研究报告了临床结局的恶化,因此,本研究使用猪AMI模型来评估比索洛尔对VA和死亡率的疗效。将20头猪分为两组,一组口服比索洛尔,在实验前给药3小时,然后维持7天。植入一个环形记录仪,通过球囊闭塞诱导AMI 60分钟,然后进行再灌注。一周后,对存活动物的超声心动图和环形记录仪数据进行分析。在冠状动脉闭塞期间,比索洛尔没有增加心率(62.9±14.5对79.0±20.3;p=0.048),没有降低室性早搏(PVC)发生率(0.8±0.8对11.0±12.8;p=0.021),也没有倾向于降低复发性VA(0.6±0.5对1.1±1.1;p=0.131)。再灌注后,比索洛尔确实降低了AMI早期的VA(0.1±0.3对4.2±4.6;p=0.001),且与心肌恢复程度无关。在这个猪模型中,早期口服比索洛尔可能有助于降低PVC和复发性VA的发生率,并确定在AMI早期效果是否更显著。我们的结果表明,在这个再灌注时代,比索洛尔可能有助于降低AMI后的致死性VA和心源性死亡。